New Clinical Research Reports EarlySense Home-Monitoring Technology Anticipates Hospital Readmission Risk for Heart Failure Patients
Home Use of EarlySense Technology Could Potentially Save Hospitals Millions of Dollars Each Year in Readmission Penalties
WALTHAM, Massachusetts, February 23, 2016 /PRNewswire/ --
EarlySense®, the leader in contact-free health sensing and analytics, announced today a new peer-reviewed study published by a leading Cleveland, Ohio, teaching institute. The investigators found that the company's novel under-the-mattress piezoelectric sensor (PS), which continuously monitors respiration rate, heart rate and motion, was well-tolerated by the congestive heart failure (CHF) patients. In addition, it was found that change in respiratory rate is an effective predictor of hospital readmission for heart failure patients.
This is the first study that followed heart failure patients after hospital discharge, and then monitored them at home using EarlySense. The purpose of the study was to gauge if an under-the-mattress PS could assist clinicians with predicting patients at risk for 30-day hospital readmission.
The study led by Bennett, Shao and Gorodeski, entitled Home Monitoring of Heart Failure Patients at Risk for Hospital Readmission Using a Novel Under-the-mattress Piezoelectric Sensor, was published in the Journal of Telemedicine and Telecare.
Researchers used a contactless under-the-mattress PS to monitor vibrations resulting from breathing, pumping of the heart, and body movements among individuals at home following hospitalization for heart failure. The objectives were to assess acceptability of the device in the home, evaluate physiological patterns, and determine if altered patterns correlate with readmission. The study also demonstrated that the average nightly respiratory rate was the most important risk-adjusted associate of readmission for heart failure.
"These sensors are designed to assist clinicians' early detection of adverse events in a non-invasive manner, providing the opportunity for intervention prior to hospitalization," said Dalia Argaman, VP of Clinical and Regulatory Affairs at EarlySense. "These data may impact the financial wellbeing of health systems facing economic penalties for 30-day readmission. Predictive insights from a monitoring solution can translate into millions of dollars saved."
Nearly six million Americans live with heart failure and more than 870,000 new cases are diagnosed each year. Frequent readmissions are a main contributor to high costs associated with heart failure in the U.S., estimated at $39 billion annually.
EarlySense provides contact-free, continuous monitoring solutions for the medical and consumer digital health markets. EarlySense's patented sensor and advanced algorithms monitor and analyze cardiac, respiratory, sleep and motion parameters. Used in hospitals and healthcare facilities worldwide, EarlySense assists clinicians in early detection of patient deterioration, helping to prevent adverse events, including code blues, preventable ICU transfers, patient falls and pressure ulcers.
The myEarlySense smart home-compatible consumer solution brings hospital-proven technology to the home, providing valuable data regarding wellness and sleep. myEarlySense OEM technology is at the core of wellness and sleep products marketed by international partners including Samsung, Beurer and iFit. EarlySense was founded in 2004 and has offices in Waltham, MA and Ramat Gan, Israel. For more information, please visit http://www.EarlySense.com and http://www.myEarlySense.com.
Follow EarlySense on LinkedIn, Twitter and Facebook.
Media Relations Contact: